242 related articles for article (PubMed ID: 36040666)
1. Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.
Kang HJ; Kwak YK; Kim M; Lee SJ
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3215-3223. PubMed ID: 36040666
[TBL] [Abstract][Full Text] [Related]
2. Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.
Tekatli H; Palacios MA; Schneiders FL; Haasbeek CJA; Slotman BJ; Lagerwaard FJ; Senan S
Radiother Oncol; 2023 Oct; 187():109823. PubMed ID: 37516364
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans.
Wojcieszynski AP; Hill PM; Rosenberg SA; Hullett CR; Labby ZE; Paliwal B; Geurts MW; Bayliss RA; Bayouth JE; Harari PM; Bassetti MF; Baschnagel AM
Technol Cancer Res Treat; 2017 Jun; 16(3):366-372. PubMed ID: 28168936
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
5. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment plans between IMRT with MR-linac and VMAT for lung SABR.
Park JM; Wu HG; Kim HJ; Choi CH; Kim JI
Radiat Oncol; 2019 Jun; 14(1):105. PubMed ID: 31196120
[TBL] [Abstract][Full Text] [Related]
7. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
8. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose.
Booth J; Caillet V; Briggs A; Hardcastle N; Angelis G; Jayamanne D; Shepherd M; Podreka A; Szymura K; Nguyen DT; Poulsen P; O'Brien R; Harris B; Haddad C; Eade T; Keall P
Radiother Oncol; 2021 Feb; 155():131-137. PubMed ID: 33152399
[TBL] [Abstract][Full Text] [Related]
9. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
12. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
[TBL] [Abstract][Full Text] [Related]
13. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous treatment of two lung cancer lesions with stereotactic MR-guided adaptive radiation therapy: A case report.
Chen F; Cheng YK; Chiang CH; Lu TY; Huang CJ
Medicine (Baltimore); 2023 Jan; 102(2):e32626. PubMed ID: 36637933
[TBL] [Abstract][Full Text] [Related]
15. A comparative planning study for lung SABR between tri-Co-60 magnetic resonance image guided radiation therapy system and volumetric modulated arc therapy.
Park JM; Park SY; Kim HJ; Wu HG; Carlson J; Kim JI
Radiother Oncol; 2016 Aug; 120(2):279-85. PubMed ID: 27401404
[TBL] [Abstract][Full Text] [Related]
16. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid
Yang DM; Palma D; Louie A; Malthaner R; Fortin D; Rodrigues G; Yaremko B; Laba J; Gaede S; Warner A; Inculet R; Lee TY
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):94-101. PubMed ID: 30281918
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
[TBL] [Abstract][Full Text] [Related]
18. Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage non-small-cell lung cancer.
Chuong MD; Kotecha R; Mehta MP; Adamson S; Romaguera T; Hall MD; Alvarez D; Gutierrez AN; Mishra V; De Zarraga F; Mittauer KE
Med Dosim; 2021 Autumn; 46(3):247-252. PubMed ID: 33648822
[TBL] [Abstract][Full Text] [Related]
19. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors.
Hayashi K; Suzuki O; Shiomi H; Ono H; Setoguchi A; Nakai M; Nakanishi E; Tatekawa S; Ose N; Hirata T; Tamari K; Seo Y; Funaki S; Isohashi F; Shimizu S; Shintani Y; Ogawa K
BMC Cancer; 2023 Mar; 23(1):215. PubMed ID: 36882702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
